Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

On February 10, 2026, Septerna, Inc., a clinical-stage biotechnology company listed on Nasdaq under the ticker SEPN, announced an inducement grant issued by its Board of Directors to Mark A. Wilson, who is serving as the Chief Legal Officer. This grant, made on February 6, 2026, comprises a non-qualified stock option allowing him to purchase 165,000 shares of the company's common stock, aligned with the terms outlined in the Company’s 2026 Inducement Plan. This award was granted as a critical component of Mr. Wilson's employment, complying with Nasdaq Listing Rule 5635(c)(4).

The stock option is priced at $25.41 per share, reflecting Septerna’s closing share price on the date of the grant. The vesting of these shares is structured to occur over a four-year period, with 25% becoming available on the one-year anniversary of the vesting commencement date, while the remaining 75% will vest in monthly installments over the following 36 months, contingent upon Mr. Wilson’s ongoing employment.

Septerna, based in South San Francisco, California, is dedicated to advancing drug discovery for G protein-coupled receptors (GPCRs), which are critical for numerous therapeutic areas. The company utilizes its proprietary Native Complex Platform® to develop oral small molecule drug candidates aimed at addressing significant unmet medical needs across fields such as endocrinology, immunology, inflammation, and metabolic diseases.

For more details on Septerna and its innovative approaches in biotechnology, interested parties can refer to the company’s website at www.septerna.com.

For investor inquiries, Renee Leck can be contacted at THRUST (renee@thrustsc.com), while media inquiries can be directed to Carly Scaduto (carly@thrustsc.com).

Septerna, Inc. (Nasdaq: SEPN) recently made headlines with its inducement stock option grant to Mark A. Wilson, its Chief Legal Officer, as part of its strategic efforts to enhance executive retention and alignment with shareholder interests. This inducement award consists of a non-qualified stock option for 165,000 shares at an exercise price corresponding to the company’s share price on February 6, 2026, and will vest over four years. The award structure requires continuous employment, underscoring Septerna's commitment to long-term performance and stability.

From a market perspective, this move signals a few critical insights for investors. First, the grant indicates that Septerna is serious about attracting top talent who can navigate the complexities of the biotech landscape, particularly in areas such as FDA approvals and complex drug development processes that characterize GPCR therapies. Wilson's experience will be instrumental as the company strengthens its pipeline, currently populated with novel oral small molecule drug candidates targeting significant unmet medical needs.

Investors should also note the stock option price of $25.41 per share is reflective of the current market valuation, positioning it as an attractive entry point for those considering a position in SEPN. A successful rollout of their clinical-stage candidates could enhance the stock's value, potentially exceeding the option price as results materialize from ongoing trials.

Moreover, Septerna's proprietary Native Complex Platform® positions the company at the cutting edge of GPCR drug discovery, thereby offering both risk and reward in a sector known for rapid advancements. As the company continues to expand its collaborations in endocrinology, immunology, and beyond, savvy investors may want to closely follow Septerna’s developments, as they could catalyze significant stock price movements and create value for shareholders in the long term.